Kineta (NASDAQ:KA) Shares Up 10% – Time to Buy?

Kineta, Inc. (NASDAQ:KA) shares traded up 10% during mid-day trading on Wednesday . The stock traded as high as $0.74 and last traded at $0.74. 28,850 shares changed hands during trading, a decline of 93% from the average session volume of 409,478 shares. The stock had previously closed at $0.67.

Kineta Stock Down 5.1 %

The company has a market capitalization of $8.58 million, a PE ratio of -0.47 and a beta of 0.46. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $0.65 and a 200 day moving average of $0.59.

Kineta (NASDAQ:KA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.20) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kineta stock. PFG Investments LLC acquired a new position in shares of Kineta, Inc. (NASDAQ:KA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 326,988 shares of the company’s stock, valued at approximately $174,000. PFG Investments LLC owned approximately 2.67% of Kineta as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 30.32% of the company’s stock.

Kineta Company Profile

Kineta, Inc is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.